サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1782007

減量薬市場：タイプ別、剤形別、用途別、流通チャネル別、国別、地域別-2025年～2032年の世界産業分析、市場規模、市場シェア、予測

Weight Loss Drugs Market, By Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.46円
減量薬市場：タイプ別、剤形別、用途別、流通チャネル別、国別、地域別-2025年～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年07月01日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

減量薬市場規模は2024年に545億322万米ドルとなり、2025年から2032年にかけてCAGR 19.29%で拡大

減量薬市場-市場力学

肥満に伴う健康リスクに対する意識の高まり

2型糖尿病、心臓病、特定のがん、呼吸障害など、肥満に伴う深刻な健康リスクに光を当てる公衆衛生キャンペーンの高まり、メディアの注目の高まり、進行中の医学調査により、体重管理がいかに重要であるかが多くの人々に認識され始めています。世界保健機関（WHO）の報告によると、1975年以来、世界の肥満率は3倍近くに増加し、2023年には19億人以上の成人が太りすぎとみなされ、そのうち6億5,000万人以上が肥満に分類されるといいます。このような意識の高まりは、これらの健康リスクを軽減するために、減量薬などの効果的な治療法を探すよう個人を駆り立てています。その結果、ヘルスケアプロバイダーは、ライフスタイルの改善とともに薬理学的治療を提案するようになってきています。このような肥満関連合併症に対する意識の高まりは、世界の減量薬需要を大幅に押し上げ、製薬会社はこの差し迫ったニーズに対応するため、より安全で効果的な選択肢を生み出すよう促しています。

例えば

2024年1月、ノボノルディスクは、主力減量薬であるウェゴビー（セマグルチド）の販売地域を複数の新しい国際市場に拡大した。この拡大は、効果的な肥満治療薬に対する世界の需要の高まりに対応するもので、ノボノルディスクが減量薬分野でリーダーシップを強化し、世界中でより多くの患者が肥満と関連する健康リスクに対処できるよう支援することを目的としています。

減量薬市場-主要インサイト

当社リサーチアナリストの分析によると、世界市場は予測期間（2025-2032年）に約19.29%のCAGRで毎年成長すると予測されています。

タイプ別セグメンテーションでは、処方薬が2024年に最大市場シェアを示すと予測されています。

剤形別では、2024年に注射剤が主要な剤形となりました。

用途別では、食欲抑制が2024年の主要用途でした。

流通チャネル別では、小売薬局が2024年の主要流通チャネルです。

地域別では、北米が2024年の売上高でトップ

減量薬市場-セグメンテーション分析：

世界の減量治療薬市場は、タイプ、剤形、用途、流通チャネル、地域によって区分されます。

市場はタイプ別に2つに分類される：市販薬（OTC）と処方薬です。処方薬セグメントは、その実証された有効性と安全性プロファイルにより、減量薬市場を独占しており、医師の監督が必要です。これらの医薬品は、代謝経路、食欲調節、脂肪吸収を特に標的とする高度な製剤を含むことが多く、中等度から重度の肥満の治療に信頼性が高いです。これらの薬剤は臨床的に検証された結果をもたらし、厳格な規制当局の承認に支えられているため、医師は好んで処方しています。さらに、肥満に関連した健康合併症の有病率の増加が、処方減量薬の医師による推奨の増加を促進しています。

市場は用途によって、食欲抑制、脂肪ブロック、その他の3つのカテゴリーに分類されます。食欲抑制剤は、中枢神経系をターゲットにして空腹感を抑え、欲求をコントロールすることにより、消費カロリーを減らし、持続的な体重減少を促進します。食事摂取を管理するこの直接的なアプローチにより、食欲抑制剤はヘルスケアプロバイダーと患者の両方にとって好ましい選択肢となっています。さらに、最近の薬剤製剤の進歩により、安全性プロファイルと有効性が向上し、患者のアドヒアランスと満足度が高まっています。肥満率が世界的に上昇を続ける中、食欲抑制剤は薬理学的体重管理の最前線にあり続け、市場の大幅な成長と技術革新を牽引しています。

減量薬市場-地理的洞察

2024年の予測期間中、北米が世界の減量薬市場を独占しています。

北米は、肥満の有病率の高さ、強力なヘルスケアインフラ、高度な薬剤へのアクセスの広さにより、減量薬市場で最大の市場シェアを占め、支配的な地域となっています。特に米国は、成人人口のかなりの部分が過体重または肥満に分類されており、この地域をリードしています。また、ウェゴビー（ノボ・ノルディスク）やゼップバウンド（イーライ・リリー）などの減量薬が早期に承認され商業的成功を収めたことが、市場の成長を後押ししています。有利な償還政策、肥満に関連する健康リスクに対する意識の高まり、政府の積極的な支援が、北米市場の優位性をさらに高めています。

アジア太平洋は、2024年の予測期間中、減量薬市場で最も高いCAGRを記録すると予測されます。

アジア太平洋は、急速な都市化、座りがちなライフスタイル、肥満率の急増につながる食生活の変化によって、最も急成長している市場として浮上しています。中国、インド、韓国などの国々では、糖尿病や心血管障害などの肥満関連疾患が急増しています。これと並行して、可処分所得の増加、ヘルスケアへのアクセスの改善、体重減少のための医薬品治療が受け入れられつつあることが需要を加速させています。さらに、肥満予防を目的としたヘルスケア構想の拡大や政府の支援による公衆衛生プログラムが、アジア太平洋での市場の急拡大を支えています。

減量薬市場-競合情勢：

減量薬市場は、製薬大手、新興バイオテクノロジー企業、肥満治療への研究開発投資の拡大が混在し、競争が激しく急速に発展しています。ノボノルディスク、イーライリリー、ファイザー、ジョンソン・エンド・ジョンソン、グラクソ・スミスクラインなどの大手企業が最前線に立ち、技術革新、臨床試験の進歩、世界の市場拡大を通じて競争しています。

ノボノルディスクは、優れた臨床成績と世界の需要の高さを示す人気薬ウェゴビー（セマグルチド）で、現在圧倒的な市場シェアを占めています。イーライリリーはゼップバウンド（チルゼパチド）で、2型糖尿病と体重減少の両作用に優れた利点を提供し、急速に手ごわい競争相手となりました。増大する需要に対応するため、両社は製造能力への大規模な投資を行い、新規市場への参入を図っています。ファイザーとGSKは、この急速に拡大する市場に参入し、その地位を向上させるため、パイプラインの研究や戦略的提携に注力しています。小規模なバイオテクノロジー企業も、カスタマイズされた肥満治療薬や革新的な作用機序で登場しています。

同市場では、有効性、安全性プロファイル、投与の利便性、長期的なアウトカムの面で競合が激化しており、各社は提携、ライセンス契約、買収を進め、市場拡大を図っています。肥満率が世界的に上昇を続ける中、減量薬市場の競合は引き続き激しく、継続的な技術革新と商業活動が促進されると予想されます。

目次

第1章 減量薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 減量薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 減量薬業界の調査

  • PESTEL分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 減量薬市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 減量薬市場情勢

  • 減量薬市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 減量薬市場- タイプ別

  • 概要
    • セグメントシェア分析（タイプ別）
    • 市販薬（OTC）
    • 処方薬

第8章 減量薬市場- 剤形別

  • 概要
    • 剤形別セグメントシェア分析
    • カプセル
    • 注射
    • 液体
    • タブレット

第9章 減量薬市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • 食欲抑制
    • 脂肪ブロッキング
    • その他

第10章 減量薬市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • オンライン薬局
    • 病院薬局
    • 小売薬局

第11章 減量薬市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 減量薬業界

  • 競合ベンチマーキング
    • Competitive Dashboard
    • Competitive Positioning
  • 企業プロファイル
    • Eli Lilly and Company
    • Amgen Inc.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd（Roche Holding AG）
    • GlaxoSmithKline plc
    • Ionis Pharmaceuticals, Inc.
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • Sanofi SA
    • Structure Therapeutics Inc.
    • Takeda Pharmaceutical Company Limited
    • VIVUS, Inc.
    • Zafgen, Inc.
    • Eisai Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV5439

REPORT HIGHLIGHT

Weight Loss Drugs Market size was valued at US$ 54,503.22 Million in 2024, expanding at a CAGR of 19.29% from 2025 to 2032.

The Weight Loss Drugs Market is the global industry that develops, makes, and sells pharmaceutical products to help people lose weight. These drugs operate in different ways, like suppressing appetite, blocking fat absorption, or boosting metabolism to manage obesity and overweight issues. The market includes prescription medications, over-the-counter products, and new therapies aimed at tackling the rising rates of obesity-related health problems around the world. The market is growing due to increased awareness of the health risks associated with obesity, more sedentary lifestyles, and a higher demand for effective and safe weight management solutions.

Weight Loss Drugs Market- Market Dynamics

Rising awareness about health risks associated with obesity

With the rise of public health campaigns, increased media attention, and ongoing medical research shining a light on the serious health risks associated with obesity like type 2 diabetes, heart disease, certain cancers, and breathing issues more people are starting to realize just how important it is to manage their weight. The World Health Organization (WHO) reports that since 1975, the global rate of obesity has nearly tripled, with over 1.9 billion adults considered overweight in 2023, and more than 650 million of those classified as obese. This growing awareness is pushing individuals to look for effective treatment options, including weight loss medications, to help mitigate these health risks. Consequently, healthcare providers are increasingly suggesting pharmacological treatments alongside lifestyle changes. This growing consciousness about obesity related complications is significantly boosting the demand for weight loss drugs worldwide, prompting pharmaceutical companies to create safer and more effective options to address this pressing need.

For Instance,

In January 2024, Novo Nordisk expanded the availability of its flagship weight loss drug, Wegovy (semaglutide), to multiple new international markets. This expansion addresses the rising global demand for effective obesity treatments and reinforces Novo Nordisk's leadership in the weight loss drugs sector, aiming to help more patients manage obesity and related health risks worldwide.

Weight Loss Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.29% over the forecast period (2025-2032)

Based on type segmentation, prescription drugs were predicted to show maximum market share in the year 2024

Based on dosage form segmentation, injections was the leading dosage form in 2024

Based on application segmentation, appetite suppression was the leading application in 2024

Based on distribution channel segmentation, retail pharmacy was the leading distribution channels in 2024

On the basis of region, North America was the leading revenue generator in 2024

Weight Loss Drugs Market- Segmentation Analysis:

The global weight loss drugs market is segmented on the basis of type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on type: Over-the-counter drugs (OTC) and prescription drugs. The Prescription Drugs segment dominates the Weight Loss Drugs Market due to their proven effectiveness and safety profile, which require medical supervision. These drugs often involve advanced formulations that specifically target metabolic pathways, appetite regulation, or fat absorption, making them more reliable for treating moderate to severe obesity. Physicians prefer prescribing these medications because they provide clinically validated results and are supported by rigorous regulatory approvals. Additionally, the growing prevalence of obesity-related health complications is driving increased physician recommendation of prescription weight loss drugs.

The market is divided into three categories based on application: appetite suppression and fat blocking and others. The appetite suppression sector dominates the market and Appetite suppressants work by targeting the central nervous system to reduce feelings of hunger and control cravings, which helps individuals consume fewer calories and promotes sustained weight loss. This direct approach to managing food intake makes appetite suppressants a preferred choice for both healthcare providers and patients. Moreover, recent advancements in drug formulations have enhanced their safety profiles and effectiveness, increasing patient adherence and satisfaction. With obesity rates continuing to rise globally, appetite suppressants remain at the forefront of pharmacological weight management, driving significant market growth and innovation.

Weight Loss Drugs Market- Geographical Insights

North America dominates the global weight loss drugs market during the forecast period in 2024.

North America is dominating region in the weight loss drugs market, accounting for the largest market share due to its high prevalence of obesity, strong healthcare infrastructure, and widespread access to advanced medications. The United States, in particular, leads the region with a significant portion of the adult population classified as overweight or obese. Additionally, the early approval and commercial success of weight loss drugs such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) have boosted market growth. Favourable reimbursement policies, growing awareness about obesity-related health risks, and active government support further contribute to North America's market dominance.

Asia Pacific is estimated to register the highest CAGR in the weight loss drugs market during the forecast period in 2024.

Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, sedentary lifestyles, and dietary changes leading to a surge in obesity rates. Countries like China, India, and South Korea are experiencing a sharp rise in obesity-related diseases such as diabetes and cardiovascular disorders. Alongside this, increasing disposable incomes, improved access to healthcare, and growing acceptance of pharmaceutical treatments for weight loss are accelerating demand. Moreover, expanding healthcare initiatives and government-backed public health programs aimed at obesity prevention are supporting the market's rapid expansion across Asia-Pacific.

Weight Loss Drugs Market- Competitive Landscape:

The weight loss drugs market is highly competitive and rapidly evolving, driven by a mix of pharmaceutical giants, emerging biotech firms, and growing R&D investments in obesity treatment. Leading players such as Novo Nordisk, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline are at the forefront, competing through innovation, clinical trial advancements, and global market expansion.

With its popular medication Wegovy (semaglutide), which has demonstrated excellent clinical outcomes and great demand worldwide, Novo Nordisk presently holds a dominant market share. With Zepbound (tirzepatide), Eli Lilly has swiftly become a formidable competitor, providing dual-action advantages for type 2 diabetes and weight loss. To keep up with the increasing demand, both businesses are making significant investments in manufacturing capacity and entering new markets. To penetrate or improve their positions in this rapidly expanding market, Pfizer and GSK are concentrating on pipeline research and strategic partnerships. Smaller biotech businesses are also making an appearance with customized obesity treatments and innovative methods of action.

The market is witnessing increased competition in terms of efficacy, safety profiles, dosing convenience, and long-term outcomes, with companies also pursuing partnerships, licensing deals, and acquisitions to expand their reach. As obesity rates continue to climb globally, the competitive intensity in the weight loss drugs market is expected to remain strong, fostering ongoing innovation and commercial activity.

Recent Developments:

In June 2025, Eli Lilly announced a strategic collaboration with Amazon Pharmacy to distribute its weight loss drug Zepbound (tirzepatide) directly to consumers. The move aims to improve patient access and convenience, while expanding Eli Lilly's digital health footprint in the obesity treatment space. This partnership supports broader adoption amid rising demand for weight management therapies.

In April 2025, Novo Nordisk acquired Emisphere Technologies, a company known for oral drug delivery systems. This acquisition is intended to improve oral formulations of semaglutide, the active ingredient in Wegovy, enhancing patient compliance and accessibility. It strengthens Novo Nordisk's innovation pipeline and supports its strategy to lead in both injectable and oral weight loss therapies.

In January 2025, Johnson & Johnson entered into a co-development partnership with a U.S.-based biotech firm to create dual-acting metabolic modulators for obesity management. The collaboration focuses on developing next-generation drugs that offer safer, long-term weight loss. This move reflects J&J's renewed strategic interest in addressing global obesity and metabolic disorders.

In October 2024, GlaxoSmithKline (GSK) launched Phase 2 clinical trials for a novel appetite suppressant targeting central nervous system pathways. This innovation is part of GSK's broader goal to expand its metabolic health portfolio with first-in-class treatments. The company aims to develop therapies that offer high efficacy with improved patient compliance and minimal side effects.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL WEIGHT LOSS DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd (Roche Holding AG)
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Structure Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS, Inc.
  • Zafgen, Inc.
  • Eisai Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Over-the-counter drugs (OTC)
  • Prescription Drugs

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Injections
  • Liquids
  • Tablets

GLOBAL WEIGHT LOSS DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Appetite Suppression
  • Fat Blocking
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

GLOBAL WEIGHT LOSS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Weight Loss Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Weight Loss Drugs Market Snippet by Type
    • 2.1.2. Weight Loss Drugs Market Snippet by Dosage Form
    • 2.1.3. Weight Loss Drugs Market Snippet by Application
    • 2.1.4. Weight Loss Drugs Market Snippet by Distribution Channel
    • 2.1.5. Weight Loss Drugs Market Snippet by Country
    • 2.1.6. Weight Loss Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Weight Loss Drugs Key Market Trends

  • 3.1. Weight Loss Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Weight Loss Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Weight Loss Drugs Market Opportunities
  • 3.4. Weight Loss Drugs Market Future Trends

4. Weight Loss Drugs Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Weight Loss Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Weight Loss Drugs Market Landscape

  • 6.1. Weight Loss Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Weight Loss Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Over-the-counter drugs (OTC)
    • 7.1.3. Prescription Drugs

8. Weight Loss Drugs Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Capsules
    • 8.1.3. Injections
    • 8.1.4. Liquids
    • 8.1.5. Tablets

9. Weight Loss Drugs Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Appetite Suppression
    • 9.1.3. Fat Blocking
    • 9.1.4. Others

10. Weight Loss Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Online Pharmacy
    • 10.1.3. Hospital Pharmacy
    • 10.1.4. Retail Pharmacy

11. Weight Loss Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Weight Loss Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Weight Loss Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Weight Loss Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Weight Loss Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Weight Loss Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Weight Loss Drugs Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Eli Lilly and Company
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca
    • 12.2.4. F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • 12.2.5. GlaxoSmithKline plc
    • 12.2.6. Ionis Pharmaceuticals, Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Merck & Co., Inc.
    • 12.2.9. Novartis AG
    • 12.2.10. Teva Pharmaceutical Industries Ltd.
    • 12.2.11. Pfizer Inc.
    • 12.2.12. Rhythm Pharmaceuticals, Inc.
    • 12.2.13. Sanofi S.A.
    • 12.2.14. Structure Therapeutics Inc.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. VIVUS, Inc.
    • 12.2.17. Zafgen, Inc.
    • 12.2.18. Eisai Co., Ltd.
    • 12.2.19. Boehringer Ingelheim International GmbH
    • 12.2.20. Currax Pharmaceuticals LLC
    • 12.2.21. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us